The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Open accessAbstract
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells. BCMA is highly expressed on plasmablasts and plasma cells from multiple myeloma (MM) patient samples. We developed a BCMAxCD3 bispecific antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ MM cell lines in vitro (H929 cells, 50% effective concentration [EC50] = 0.15 nM; MM.1R cells, EC50 = 0.06 nM; RPMI 8226 cells, EC50 = 0.45 nM) with concomitant T-cell activation (H929 cells, EC50 = 0.21 nM; MM.1R cells, EC50 = 0.1 nM; RPMI 8226 cells, EC50 = 0.28 nM) and cytokine release. This activity was further increased in the presence of a γ-secretase inhibitor (LY-411575). Teclistamab also depleted BCMA+ cells in bone marrow samples from MM patients in an ex vivo assay with an average EC50 value of 1.7 nM. Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells. Antitumor activity of teclistamab was also observed in 2 BCMA+ MM murine xenograft models inoculated with human T cells (tumor inhibition with H929 model and tumor regression with the RPMI 8226 model) compared with vehicle and antibody controls. The specific and potent activity of teclistamab against BCMA-expressing cells from MM cell lines, patient samples, and MM xenograft models warrant further evaluation of this bispecific antibody for the treatment of MM. Phase 1 clinical trials (monotherapy, #NCT03145181; combination therapy, #NCT04108195) are ongoing for patients with relapsed/refractory MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This effect occurs regardless of T-cell–receptor specificity or major histocompatibility complex class I molecules on the surface of myeloma cells.18”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [18]
In the citing paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [18]
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978 · cited 1×
“MM is characterized by overproduction of M protein, which can lead to bone lesions, increased susceptibility to infections, anemia, hypercalcemia, and renal insufficiency.(2) Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape o…”
BackgroundPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382 · cited 1×
“Multiple myeloma (MM) is a malignant plasma cell disorder that leads to clonal proliferation of terminally differentiated plasma cells in the bone marrow (BM) and accounts for ;10% of all hematologic cancers.(1) MM is characterized by overproduction of M protein, which can lead to bone lesions, increased susceptibilit…”
BackgroundRaje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · cited 1×
“Therapeutic approaches such as chimeric antigen receptor T-cell therapies and bispecific T-cell engagers that use T cell–mediated cytotoxicity to target BCMA on plasma cells have shown deep responses in patients with relapsed or refractory disease.(21-25) Another class of T-cell redirecting therapy in development for…”
BackgroundElotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J. V., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J. E., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,175 · cited 2×
“Upon binding to its ligands, a proliferation-inducing ligand (APRIL; CD256) and BAFF (CD257), BCMA activates p38/NF-kB and induces upregulation of antiapoptotic proteins to regulate B-cell maturation, proliferation, and survival.(16-20) Increased levels of a soluble form of BCMA (sBCMA), produced through cleavage at t…”
BackgroundTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundRichardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861 · cited 1×
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
Background
Cited by
Sorted by citations
Items 101–144 of 144
McCurdy, A. B. R., Reece, D. E., Louzada, M., White, D. J., Parkin, S., Chu, M. P., Kotb, R. R., Mian, H. S., Othman, I., Su, J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01135-2 · Cited by 4
Saba, L., Fu, C., Liang, H., & Chaulagain, C. P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.006 · Cited by 3
Gevertz, J. L., & Kareva, I. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70105 · Cited by 2
“The molecular weight of membrane-bound BCMA is approximately 20 kDa [19].”
ABBV-303 Is an NK-cell Engager Specific for c-Met–Expressing Tumors
Stone, J. D., Fish, K., Ashok, D., McKay, L. M., Akhand, S. S., DiGiammarino, E. L., Inzunza, H. D., Palma, J. P., Cosgrove, C., Ellis, P. A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0820 · Cited by 2
TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS
Lim, S. A., Agard, N. J., Kelly, R. L., Bell, B. N., Chen, S.-J., Gram, A. M., Merritt, J. R., Moench, I., Pance, K., & Petojevic, T. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch25 · Cited by 2
Frebel, K., Albring, J. C., Wohlgemuth, A., Schwöppe, C., Hailfinger, S., Lenz, G., & Stelljes, M. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011647 · Cited by 2
“Previous studies have established that IV administration of the mAb 145-2C11, which was used in the construction of Slamf7-BiTE, can induce clinical and laboratory manifestations reminiscent of those observed in patients suffering from CRS.”
BackgroundInfluentialvan Voss, M. R. H., Molenaar, R. J., Korst, C. L. B. M., Bartelink, I. H., Baglio, S. R., Kruyswijk, S., de Ruijter, M. E. M., Zweegman, S., Kuipers, M. T., & van de Donk, N. W. C. J. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2397436 · Cited by 2
“In vitro anti-BCMA antibody binding and cytotoxicity were found to be reduced in the presence of high concentrations of sBCMA at levels that can be present in MM patients [65,66].”
Tai, W., Wahab, A., Franco, D., Shah, Z., Ashraf, A., Abid, Q., Mohammed, Y. N., Lal, D., & Anwer, F. (2022) · Antibodies · doi:10.3390/antib11020022 · Cited by 2
“Teclistamab (also known as JNJ-64007957 or JNJ-7957) is another BCMA × CD3 bispecific T-cell engager IgG4 antibody that was developed using Genmab DuoBody technology and mediates T-cell-redirected killing of myeloma cells [84].”
MethodLutz, R., Friedrich, M., Raab, M. S., Weinhold, N., & Goldschmidt, H. (2021) · Cancers · doi:10.3390/cancers13164135 · Cited by 1
Biology and Clinical Evaluation of T/NK Cell Engagers
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_17 · Cited by 1
Eriksen‐Stapleton, D., King, M., Dong, G., Srivastava, D., Iskra, T., Aho, V., Nguyen, K., Ingaharro, L., Scarcelli, J. J., Ochocki, J. D., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28975 · Cited by 1
“Additionally, the parental homodimers are typically less engineered than KiH ‐ based molecules and are more similar to the bioprocessing characteristics commonly observed for well ‐ understood monospecific antibody therapeutics (Neijssen et al. 2021; Pillarisetti et al. 2020; Yao et al. 2023).”
Integrative and Emerging Models in Antibody Research: A Comprehensive Review
Devasani, J. R., Guntuku, G., sarabu, P., Muthyala, M. K. K., Palla, M. S., & Volety, M. S. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf018 · Cited by 2
To treat or not to treat: a state-of-the-art overview of smoldering multiple myeloma
Garg, A., & Devarakonda, S. S. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2025.1706219 · Cited by 1
Piron, B., Moreau, P., & Touzeau, C. (2026) · Biologics · doi:10.2147/btt.s539066 · Cited by 3
Jiao, G., Peng, H., Yang, Y., Liu, Y., Liu, X., Hu, Y., Dai, Y., Li, Z., & Zhao, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02685-8 · Cited by 1
“Preclinical studies demonstrate that Teclistamab effectively eliminates BCMA-positive multiple myeloma (MM) cell lines and promotes robust T-cell activation even in vitro and in vivo [30].”
Mestiri, S., Assami, L., Yoosuf, Z. S. K. M., Fernandes, Q., El-Ella, D. M. A., Elsabah, H., Merhi, M., Makni‐Maalej, K., Cherif, H., Dermime, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1822508 · Cited by 1
Maroun, J. A. (2011) · Current Oncology · doi:10.3747/co.v18i0.957 · Cited by 1
Razzo, B. M., & Garfall, A. L. (2023) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2023.19.1.46 · Cited by 1
“48,49 The first in-human trial with teclistamab, MajesTEC-1, was an open-label, single-arm phase 1/2 (phase 1 ClinicalTrials. gov identifier: NCT03145181; phase 2 ClinicalTrials. gov identifier: NCT03145181) trial that evaluated intravenous (phase 1) and subcutaneous (phase 1 and 2) administration.”
BackgroundMyélome multiple et anticorps bispécifiques
Escure, G., & Manier, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.10.003
Li, L., Chen, X., Li, Y., & Lou, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1448287/v1
Self-citationB-Cell-Maturation-Antigen (BCMA) als Target in der Myelomtherapie
Frenking, J. H., Sester, L. S., & Raab, M. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-1981-0034
Etxebeste, A. (2023) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · doi:10.15581/10171/69185
Bispecific antibodies in hematological malignancies
Wayhs, C. A. Y., & Dias, D. D. O. (2024) · RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · doi:10.51126/revsalus.v6i1.640
Teclistamab, cambiando el paradigma de pacientes con Mieloma Múltiple
Funes, M. (2024) · Revista Hematología · doi:10.48057/hematologa.v28i1.584
Teclistamab for Multiple Myeloma Therapy: A Literature Review and the First Clinical Use in Russia
Semenova, A., Лучинин, А. С., Субботин, А. С., Tumyan, G. S., Arakelyan, A. V., Cherencova, A. I., & Kamyshanov, S. S. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-4-388-394
Serological pseudoprogression of multiple myeloma after treatment with teclistamab
Daunov, M., Alagha, I., Rashidi, A., Chaekal, O.-K., van Besien, K., Kapp, M., & Ignatz-Hoover, J. J. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2595221
“…is a Bispecific t-cell engager (Bite) that targets both t cell Cd3 and B-cell Maturation Antigen (BCMA) expressed on the surface of myeloma cells [4]. herein, we present a case of a 63-year-old patient with igG Lambda myeloma who developed acute kidney injury after initiating teclistamab. renal…”
Greenberg, R. S., Ruddy, J. A., Boyarsky, B. J., Werbel, W. A., Garonzik‐Wang, J., Segev, D. L., & Imus, P. H. (2021) · Figshare · doi:10.6084/m9.figshare.17696394
Sourcing and screening human antibody repertoires for discovering biotherapeutics
Abdiche, Y. N., & Hoet, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00062-5
Bayly-McCredie, E., Prince, H. M., Yannakou, C. K., Fiorenza, S., & Wisniowski, B. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2634055
“Other BCMA-targeting BsAbs have demonstrated cytotoxic activity at lower levels of BCMA receptors/cell in preclinical studies (e.g. as low as 918 receptors/cell with linvoseltamab and 2451 receptors/cell with teclistamab) [28,42].”
A New IgG-λ Band during Therapy in Light-Chain Myeloma
Swartchick, C. B., Larkin, J. M., Kohlhagen, M., Murray, D. L., & Willrich, M. A. V. (2026) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfag004
Schjesvold, F. H., Spencer, A. G., Cohen, Y. C., Ocio, E. M., López‐Pardo, J., Cafro, A. M., Callander, N. S., Kaufman, J. L., Mohan, M., Wermke, M., et al. (2026) · Cancer · doi:10.1002/cncr.70341
Du, L., Jiang, Y., Zhou, Q., & Xu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1830089
“…further restrict T-cell proliferative capacity and durability, thereby impairing the depth and persistence of BsAb-induced antitumor responses (94, 95) Finally, CD8 + T-cell exhaustion, a hallmark of MM-associated immune dysfunction, is closely linked to the immunosuppressive activity of Tregs.”
Bellout, H. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01624-0
Ellayan, D. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag203
Herzberg, F., Lu, F., Korenkov, M., Fregona, V., Didoss, C., Heisterkamp, N., Sprechert, M., Polici, A., Heck, C., Haas, S. F., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03047-5
“By crosslinking CD3 on T cells to myeloma surface antigens, TCEs promote immune synapse formation, T cell activation and clonal T cell expansion [6, 7].”
Qi, J., Park, D., Shah, P., & Akhtari, M. (2026) · Hematology Reports · doi:10.3390/hematolrep18040054
“Teclistamab is a bispecific antibody targeting both CD3 on T cells and BCMA on myeloma cells, resulting in T-cell-mediated cytotoxicity of BCMA-expressing myeloma cells [7–9].”
Thomas, J., Xu, G., Lock, H., Song, Q., Yin, Y., Luo, W., Hong, K., Lou, L., Wang, C., Chinn, L., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2718587
“32 Together with the comparable or higher BCMA affinity of gamgertamig relative to the teclistamab analog, these findings suggest that soluble BCMA may not fully abrogate gamgertamig activity, although direct studies will be needed to confirm this.”
Fc-engineering for improved cancer immunotherapy
Borgman, E., Gall, C. M. L., Ploegh, H. L., & Pishesha, N. (2026) · Biochemical Society Transactions · doi:10.1042/bst20250554
Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025
Zhang, T., Wang, S., Li, X., Li, X., & Wu, Y. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2711554
Cani, L., Puppi, M., Corcione, S., Liberatore, C., Mangiacavalli, S., Barilà, G., Giannella, M., Annibali, O., Romano, A., Girmenia, C., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.003
Teclistamab Response- and Relapse-Related Immune Correlates in the MajesTEC-1 China Cohort
Xu, H., Wang, F., Vishwamitra, D., Yang, H., Davis, C., Boominathan, R., Wu, D., Niu, Z., Song, Y., Song, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.014
Self-citationO’Neill, C. A., Broekmans, M. E. C., Korst, C. L. B. M., Krevvata, M., Collo, G. D., Groen, R. W. J., Li, B., Baglio, S. R., Philippar, U., Pillarisetti, K., et al. (2026) · HemaSphere · doi:10.1002/hem3.70487
Self-citationDysregulation of the Bone Marrow Immune Microenvironment and Clinical Outcomes in Multiple Myeloma
Ghirardi, M. P., Brandalise, P., Berraondo, M., Seehaus, C. M., de Farias, D. L. C., Pericole, F. V., Magalhães, R. J. P., Crusoé, E. D. Q., Maiolino, Â., Hungria, V., et al. (2026) · Immuno · doi:10.3390/immuno6040066
“Antimyeloma activity was demonstrated across MM cell-line systems, ex vivo patient-derived bone marrow samples, and whole-blood assays, with additional antitumor activity observed in xenograft models [80].”
Wang, Z., Feng, D., Zhang, S., Xu, S., Shen, X., Lee, R. J., Tang, Y., Xie, J., Wu, X., & He, X. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.183583
Metadata
- Authors
- Pillarisetti, K., Powers, G., Luistro, L., Babich, A., Baldwin, E., Li, Y., Zhang, X., Mendonça, M., Majewski, N., Nanjunda, R., Chin, D., Packman, K., Elsayed, Y., Attar, R., & Gaudet, F.
- Affiliations
- Oncology and
- Janssen Research & Development (United States) (US)
- IBM (United States) (US)
- Legend Biotech (United States) (US)
- Century Therapeutics (United States) (US)
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2020-09-21
- Volume
- 4
- Issue
- 18
- Pages
- 4538-4549
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC7509877
- OpenAlex
- W3087111554
- Cited by
- 144
- References
- 40
- Citations by year
- 2026: 23 · 2025: 21 · 2024: 31 · 2023: 27 · 2022: 19 · 2021: 20 · 2020: 1
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- teclistamab, BCMA, multiple myeloma, bispecific antibodies, T cell redirection, T cell activation, gamma-secretase inhibitors, tumor cell lysis, xenograft models, relapsed/refractory multiple myeloma
- MeSH terms
- Animals, Humans, Lymphocyte Activation, Multiple Myeloma, T-Lymphocytes, Antibodies, Bispecific, Mice, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
